JAMA子刊：降脂效果看不见！科学家借助新的成像方法发现，PCSK9抑制剂+他汀让动脉中有害斑块减小，且更稳定丨临床大发现

总的来说，这项深入研究强调了PCSK9抑制对于降脂、有利于黄褐色的最重要关键作用。

强化降脂对黄褐色的影响

所需提醒的是，该项深入研究尚未关注到用药全过程中会LDL-C下降的一段时间点，而且对于12个月之后的临床疗效不曾确定，这有待于日后的科研探索。

参照文献：

[1]Sánchez-Bacaicoa C, Galán J, Guijarro C, et al. Sustained low-density lipoprotein-cholesterol <70 mg/dl is associated with improved cardiovascular outcomes in the clinical setting [published online ahead of print, 2021 Dec 14]. Eur J Clin Invest. 2021;e13732. doi:10.1111/eci.13732

[2]Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, Hucko T,Aradi D, Herrman J-PR, Hermanides RS, Wang B, Wang H, Butters J, Di Giovanni G, Jones S, PompiliG, Psaltis PJ, Effect of Evolocumab on Changes in Coronary Plaque Phenotype and Burden in StatinTreated Patients Following Myocardial Infarction, JACC: Cardiovascular Imaging (2022). doi:

doi.org/10.1016/j.jcmg.2022.03.002.

[3]Game-changing new therapy to lower cholesterol and stabilise plaques associated with heart attack[EB/OL].

[5]Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Coronary Plaque Composition. J Am Coll Cardiol. 2018;72(17):2012-2021.doi:10.1016/j.jacc.2018.06.078